Active, not recruitingInterventional · Phase 3NCT01901094 ↗A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Active, not recruitingInterventional · Phase 3NCT02954874 ↗A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant ChemotherapyEleni AndreopoulouPIInterventionProcedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation TherapyDatesJan 2017 – Aug 2026SponsorSouthwest Oncology GroupBreast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more
Active, not recruitingInterventional · Phase 1/2NCT03304080 ↗A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast CancerEleni AndreopoulouPIInterventionDrug: Anastrozole · Drug: Palbociclib · Drug: Trastuzumab · Drug: PertuzumabDatesDec 2017 – Jul 2027 (est.)SponsorIcahn School of Medicine at Mount SinaiBreast NeoplasmsBreast Diseases
Active, not recruitingInterventional · Not applicableNCT03400215 ↗Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast CancerGene KimPIInterventionDiagnostic test: Diagnostic Breast Cancer Scan · Diagnostic test: Research Scan for Gradient-echo Spectroscopic Imaging (GSI)DatesJul 2018 – Apr 2026 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
RecruitingInterventional · Phase 1/2NCT03449238 ↗Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsSilvia Chiara FormentiPIInterventionDrug: PembrolizumabDatesNov 2018 – Dec 2028 (est.)SponsorWeill Medical College of Cornell UniversityMetastatic Breast CancerBrain Metastases
Active, not recruitingInterventional · Phase 3NCT03488693 ↗TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerHani Lamie AshamallaPIInterventionRadiation: Radiation · Other: No RadiationDatesOct 2018 – Sep 2027 (est.)SponsorCanadian Cancer Trials GroupBreast Cancer
Active, not recruitingInterventional · Phase 3NCT03725059 ↗A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)Eleni AndreopoulouPIInterventionBiological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: SurgeryDatesDec 2018 – Jan 2031 (est.)SponsorMerck & Co., Inc.Breast Cancer
RecruitingInterventional · Phase 2NCT03804944 ↗Converting HR+ Breast Cancer Into an Individualized VaccineSilvia Chiara FormentiPIInterventionRadiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301DatesMar 2020 – Dec 2026 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
RecruitingInterventional · Phase 2NCT03990896 ↗Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialMassimo CristofanilliPIInterventionDrug: TalazoparibDatesNov 2021 – Mar 2027 (est.)SponsorThe General Hospital Corporation (dba Massachusetts General Hospital)Breast Cancer
Active, not recruitingInterventional · Phase 1NCT04052555 ↗A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerEleni AndreopoulouPIInterventionDrug: Berzosertib · Procedure: Biospecimen Collection · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation TherapyDatesSep 2020 – Feb 2027 (est.)SponsorNational Cancer InstituteBilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
Active, not recruitingInterventional · Phase 3NCT04175210 ↗Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)Silvia Chiara FormentiPIInterventionRadiation: Radiation therapy - 3 weeks · Radiation: Radiation therapy - 2 weeksDatesNov 2019 – Jul 2025· Results postedSponsorWeill Medical College of Cornell UniversityBreast Cancer
RecruitingInterventional · Phase 2NCT04220476 ↗CIMER: Combined Immunotherapies in Metastatic ER+ Breast CancerSilvia Chiara FormentiPIInterventionRadiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) · Drug: Letrozole 2.5Mg Tab · Drug: Palbociclib 125mgDatesMar 2020 – Dec 2025 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
Active, not recruitingInterventional · Phase 2NCT04316117 ↗FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATUREEleni AndreopoulouPIInterventionProcedure: Computed Tomography · Other: Fludeoxyglucose F-18 · Procedure: Positron Emission TomographyDatesSep 2020 – Aug 2027 (est.)SponsorECOG-ACRIN Cancer Research GroupAnatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more
RecruitingInterventional · Not applicableNCT04371913 ↗Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical StudyJohn NgPIInterventionRadiation: 600cGY x 5 fractions APBI · Radiation: 270cGy x 15 fractions WBRTDatesJun 2020 – Dec 2030 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
RecruitingInterventional · Phase 2NCT04563507 ↗CIMER: Combined Immunotherapies in Metastatic ER+ Breast CancerGunisha KaurPIInterventionRadiation: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions) · Drug: Letrozole 2.5Mg Tab · Drug: Palbociclib 125mgDatesNov 2020 – Oct 2027 (est.)SponsorWeill Medical College of Cornell UniversityBreast Cancer
Active, not recruitingInterventional · Phase 1NCT04704661 ↗Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Despina SiolasPIInterventionProcedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Ceralasertib · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Procedure: Positron Emission Tomography · Biological: Trastuzumab DeruxtecanDatesAug 2021 – Mar 2027 (est.)SponsorNational Cancer InstituteAdvanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more
Active, not recruitingInterventional · Phase 3NCT04784715 ↗Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)Eleni AndreopoulouPIInterventionDrug: Trastuzumab deruxtecan · Drug: Placebo · Drug: Taxane · Drug: Pertuzumab · Drug: TrastuzumabDatesApr 2021 – May 2027 (est.)SponsorAstraZeneca, PLCBreast CancerHER2-positiveMetastatic
Active, not recruitingInterventional · Phase 3NCT04964934 ↗A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch StudyMassimo CristofanilliPIInterventionDrug: AZD9833 · Drug: AZD9833 Placebo · Drug: Anastrozole · Drug: Anastrozole placebo · Drug: Letrozole · Drug: Letrozole placebo · Drug: Palbociclib · Drug: Abemaciclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist · Drug: RibociclibDatesJun 2021 – Jun 2025SponsorAstraZeneca, PLCER-Positive HER2-Negative Breast Cancer
Active, not recruitingInterventional · Phase 2NCT05090358 ↗Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast CancerEleni AndreopoulouPIInterventionDietary supplement: Ketogenic Diet · Dietary supplement: Low Carbohydrate Diet · Drug: Alpelisib · Drug: Fulvestrant · Drug: CanagliflozinDatesOct 2021 – Oct 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterBreast CancerBreast Cancer Stage IVMetastatic Breast Cancer
RecruitingInterventional · Not applicableNCT05190978 ↗Randomized Feasibility Trial for Mesh in Pre-Pectoral ReconstructionDavid M. OtterburnPIInterventionDevice: Acellular Dermal Matrix · Procedure: Reconstruction without ADMDatesOct 2022 – Apr 2027 (est.)SponsorUniversity of California, Los AngelesBreast CancerBreast ImplantComplications, Infection or Inflammation